Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation.
Dendritic cells (DC) play a major role in the pathogenesis of graft-vs-host disease (GvHD). Directed modification of surface molecules on DC that provide instructive signals for T cells may create a tolerogenic DC phenotype that affects GvHD severity. To investigate the impact of the mammalian target of rapamycin (mTOR) inhibitor rapamycin (RAPA) on in vivo migratory capacities, tolerogenic function, and B7 superfamily surface expression on DC following allogeneic hematopoietic cell transplantation (aHCT), we generated a platform for magnetic resonance imaging and bioluminescence imaging based cell trafficking studies. Luciferase transgenic DC were labeled with superparamagnetic iron oxide nanoparticles bound to a murine IgG Ab that allowed for Fc-gammaR-mediated endocytosis. Locally injected luc(+) DC could be tracked within their anatomical context by bioluminescence imaging and magnetic resonance imaging after aHCT, based on stable intracellular localization of superparamagnetic iron oxide-IgG complexes. RAPA preconditioned DC (DC-R) displayed reduced expression of MHC class II, B7-1 (CD80), and B7-2 (CD86) but not B7-H4 whose ligation of T cells has a profound inhibitory effect on their proliferation and cytokine secretion. DC-R of recipient genotype reduced GvHD severity that is compatible with their tolerogenic phenotype. CCR5, CCR7, and CD62L expression was not affected by mTOR inhibition, which allowed for DC-R in vivo trafficking to secondary lymphoid compartments where immunregulation is required. This study is the first to delineate the impact of RAPA on DC migration and tolerogenic function after aHCT. Modification of the DC phenotype by mTOR inhibition may have therapeutic potential in an attempt to reduce GvHD following aHCT.
Reichardt
Wilfried
W
Department of Diagnostic Radiology and Medical Physics, Freiburg University Medical Center, Albert-Ludwigs-University, Freiburg, Germany.
Dürr
Christoph
C
von Elverfeldt
Dominik
D
Jüttner
Eva
E
Gerlach
Ulrike V
UV
Yamada
Mayumi
M
Smith
Benjie
B
Negrin
Robert S
RS
Zeiser
Robert
R
D000818:Animals; D016026:Bone Marrow Transplantation / Q000276:immunology*; D002465:Cell Movement / Q000187:drug effects / Q000276:immunology*; D003713:Dendritic Cells / Q000276:immunology / Q000378:metabolism / Q000637:transplantation*; D003911:Dextrans; D052203:Ferrosoferric Oxide; D018380:Hematopoietic Stem Cell Transplantation; D007108:Immune Tolerance / Q000187:drug effects; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D007501:Iron / Q000378:metabolism; D049449:Luminescence; D008221:Lymphoid Tissue / Q000166:cytology* / Q000187:drug effects / Q000276:immunology; D008279:Magnetic Resonance Imaging; D058185:Magnetite Nanoparticles; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D053758:Nanoparticles; D010087:Oxides / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D011494:Protein Kinases / Q000378:metabolism* / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects / Q000276:immunology; D020123:Sirolimus / Q000008:administration & dosage; D058570:TOR Serine-Threonine Kinases
D003911:Dextrans; D007166:Immunosuppressive Agents; D058185:Magnetite Nanoparticles; D010087:Oxides; D047428:Protein Kinase Inhibitors; D007501:Iron; D011494:Protein Kinases; C546843:mTOR protein, mouse; D058570:TOR Serine-Threonine Kinases; C065507:ferumoxides; D020123:Sirolimus; D052203:Ferrosoferric Oxide
Transplantation. 2000 Feb 27;69(4):691-3
10708136
J Immunol. 2007 Jun 1;178(11):7018-31
17513751
Blood. 2001 Jul 1;98(1):174-80
11418477
Science. 2002 Mar 15;295(5562):2097-100
11896281
Blood. 2002 Aug 1;100(3):1084-7
12130531
Transplant Proc. 2002 Aug;34(5):1394-5
12176411
Transplantation. 2003 Jan 15;75(1):137-45
12544886
Blood. 2003 Feb 15;101(4):1439-45
12393532
Annu Rev Immunol. 2003;21:685-711
12615891
Blood. 2003 Jun 1;101(11):4457-63
12531798
Magn Reson Med. 2003 Jun;49(6):1006-13
12768577
Immunity. 2003 Jun;18(6):849-61
12818165
Blood. 2003 Sep 1;102(5):1601-5
12730113
Nat Med. 2003 Sep;9(9):1144-50
12925844
Int J Hematol. 2003 Oct;78(3):181-7
14604275
Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):221-6
14688412
J Exp Med. 1986 Apr 1;163(4):998-1011
3512763
J Exp Med. 1998 Jul 6;188(1):181-91
9653094
J Exp Med. 1998 Jul 20;188(2):373-86
9670049
Science. 1999 Jul 16;285(5426):412-5
10411505
Blood. 2005 Mar 1;105(5):2227-34
15522961
Blood. 2005 Jun 15;105(12):4743-8
15746082
Blood. 2005 Aug 1;106(3):1113-22
15855275
Nat Biotechnol. 2005 Aug;23(8):983-7
16041364
Nat Biotechnol. 2005 Nov;23(11):1407-13
16258544
Nat Immunol. 2006 Jan;7(1):83-92
16311599
Blood. 2006 Jul 1;108(1):390-9
16522809
J Exp Med. 2006 Jul 10;203(7):1629-35
16785312
Transplantation. 2006 Sep 27;82(6):826-34
17006331
J Immunol. 2006 Dec 15;177(12):8338-47
17142730
Int J Cancer. 2007 Mar 1;120(5):978-84
17163419
Transplant Proc. 2007 Jan-Feb;39(1):286-8
17275524
Blood. 2007 Mar 1;109(5):2225-33
17068147
Blood. 2007 Apr 1;109(7):3108-14
17138818
Cancer Res. 2007 Jun 1;67(11):5070-5
17545582
Blood. 2008 Jan 1;111(1):453-62
17967941
Blood. 2001 May 15;97(10):2923-31
11342413